login
login

Europe Daily Bulletin No. 7879

12 January 2001
Contents Publication in full By article 38 / 49
ECONOMIC INTERPENETRATION / (eu) pharmaceuticals

The ROCHE group and its biotechnology subsidiary GENENTECH have sealed a $187 million deal with the American firm OSI PHARMACEUTICALS to develop and market an anti-cancer product.

Contents

A LOOK BEHIND THE NEWS
THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION